• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » HHS to supply vulnerable populations with 30M more Abbott rapid antigen tests

HHS to supply vulnerable populations with 30M more Abbott rapid antigen tests

December 18, 2020 By Nancy Crotti

Abbott's BinaxNow COVID-19 Ag Card COVID-19 corona virus
Abbott’s BinaxNow COVID-19 Ag Card [Image courtesy of Abbott]
The U.S. Department of Health and Human Services announced it will purchase an additional 30 million Abbott (NYSE:ABT) BinaxNOW tests for a variety of groups vulnerable to COVID-19.

Recipients will include nursing homes, assisted living facilities, home healthcare, hospice organizations, historically black colleges and universities, Native American tribes and other vulnerable groups, the agency announced.

The 30 million tests are in addition to the 150 million Abbott BinaxNOW tests that HHS and the Department of Defense bought in August and allocated to the states. Shipments of the original state allotments of BinaxNOW tests are expected to be completed in January 2021.

HHS also announced it plans to continue to provide weekly shipments of SARS-CoV-2 sample collection supplies such as swabs and transport media to states and territories through at least March 2021 and likely longer. And the agency is working with the General Services Administration to streamline the process for states, territories, and other government agencies to purchase point-of-care diagnostic tests, starting with BinaxNOW.

A contract between the federal government and Abbott Diagnostics Scarborough will enable states, territories and tribes to purchase tests at a fixed price. The contract eliminates the need for states and territories (as well as federal agencies) to negotiate and individual purchasing contracts with manufacturers and, most importantly, provides a consistent source of supplies, according to HHS. State officials complained early in the pandemic that they were competing with each other and the federal government for critical supplies, including personal protective equipment.

The maximum number of tests that states and territories will be able to purchase each month will be predetermined to help ensure adequate supplies for all on an ongoing basis. The program is expected to launch in mid-January.

Filed Under: Business/Financial News, Diagnostics, Distribution, Featured Tagged With: Abbott, coronavirus, COVID-19, U.S. Department of Health and Human Services

More recent news

  • A new way to monitor glucose: Glucotrack explains 3-year CBGM implant technology
  • Dexcom continues advances in AI for CGM, type 2 diabetes awareness
  • Tandem continues to deliver more options, benefits for those with diabetes
  • Breaking: Sequel to launch twiist automated insulin delivery system next month
  • Dexcom shares U.S. report on CGM benefits for type 2 diabetes

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy